drugset / Trial / NCT00162474
Determinants of Warfarin Metabolism
NaSingle-groupOpen-labelOther
Summary
The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin. The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.
Timeline
- Start
- 2003-09
- Primary completion
- 2030-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAF312 | Unknown | — | — |
| Subject | Dicloxacillin | Small molecule | — | — |
| Subject | Flurbiprofen | Small molecule | — | — |
| Subject | Hydrochlorothiazide | Unknown | — | — |
| Subject | Losartan | Other / unclassified | — | — |
| Subject | Phenytoin | Unknown | — | — |
| Subject | Warfarin | Small molecule | — | — |
Indications
No indication recorded.